Pannysylvania Magazine

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Metastatic Prostate Cancer Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of Metastatic Prostate Cancer, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Metastatic Prostate Cancer Market

• The metastatic prostate cancer market in the 7MM is expected to grow significantly during the forecast period from 2026 to 2036.

• The total market of Metastatic Prostate Cancer was valued at approximately USD 7.7 billion in the United States in 2025.

• The United States accounted for the largest metastatic prostate cancer market size among the 7MM in 2025.

• According to DelveInsight’s assessment, the United States had approximately 3.86 million prevalent cases of prostate cancer in 2025, while the five-year prevalent cases were nearly 1.16 million.

• Approximately 43% of metastatic prostate cancer cases were attributed to metastatic castration-resistant prostate cancer (mCRPC), while 57% were attributed to metastatic castration-sensitive prostate cancer (mCSPC).

• In 2025, the United States recorded approximately 72,500 cases of mCSPC.

• Japan accounted for approximately 24,100 cases of mCRPC in 2025.

• Leading metastatic prostate cancer companies such as Pfizer, Merck, Orion, Curium, Telix Pharmaceuticals, AstraZeneca, Novartis, Exelixis, Ipsen Pharma, Takeda, Merus, Bristol Myers Squibb, Arvinas, and others are actively developing novel therapies to address unmet treatment needs.

• Promising metastatic prostate cancer therapies in development include Opevesostat (MK-5684), Mevrometostat (PF-06821497), 177Lu-DOTA-rosopatamab (TLX591), 177Lu-PSMA-I&T, CABOMETYX, PT-112, ARV-766, FPI-2265, TRUQAP, CAN-2409, and others.

Keen to know more about the market? Request our sample page.

https://www.delveinsight.com/sample-request/metastatic-prostate-cancer-market

Key Factors Driving the Metastatic Prostate Cancer Market

• The increasing prevalence of prostate cancer and growing geriatric population are major factors driving market growth. Improved screening approaches and advances in diagnostic technologies are enabling earlier detection and better disease management.

• The growing adoption of androgen deprivation therapy (ADT) in combination with androgen receptor pathway inhibitors such as XTANDI, ERLEADA, NUBEQA, and ZYTIGA is improving clinical outcomes and expanding treatment opportunities.

• The emergence of targeted therapies, PARP inhibitors, radioligand therapies, PSMA-targeted agents, bispecific antibodies, PROTAC degraders, and immunotherapies is reshaping the metastatic prostate cancer treatment paradigm and creating significant market opportunities.

• The increasing focus on precision medicine and biomarker-driven treatment approaches is expected to enhance treatment efficacy and support market growth over the forecast period.

Metastatic Prostate Cancer Competitive Landscape

The metastatic prostate cancer pipeline remains highly active, with several promising candidates progressing through mid- and late-stage clinical development. Key pipeline therapies include Opevesostat (Merck and Orion), Mevrometostat (Pfizer), 177Lu-DOTA-rosopatamab (Telix Pharmaceuticals), 177Lu-PSMA-I&T (Curium), CABOMETYX (Exelixis, Ipsen Pharma, and Takeda), ARV-766 (Arvinas and Novartis), PT-112 (Promontory Therapeutics), FPI-2265 (AstraZeneca), and others.

These therapies target multiple pathways, including PSMA-directed radioligand therapy, CYP11A1 inhibition, EZH2 inhibition, tyrosine kinase inhibition, AKT inhibition, and protein degradation mechanisms. Their anticipated launches are expected to significantly alter the competitive landscape and improve patient outcomes.

Discover more about therapies set to grab major Metastatic Prostate Cancer market share.

Recent Developments in the Metastatic Prostate Cancer Market

• In December 2025, Telix Pharmaceuticals announced that the first patient had been dosed in Part 2 of the ProstACT Global Phase III study evaluating TLX591 in patients with mCRPC.

• In June 2025, the US FDA approved NUBEQA for the treatment of adult patients with metastatic castration-sensitive prostate cancer.

• In May 2025, longer-term follow-up results from the Phase III ARCHES study demonstrated a 30% reduction in the risk of death among patients with metastatic hormone-sensitive prostate cancer treated with XTANDI plus ADT.

• In April 2025, AstraZeneca announced the discontinuation of the CAPItello-280 Phase III trial evaluating TRUQAP in combination with docetaxel and ADT in patients with mCRPC.

• In November 2024, Curium announced that its pivotal Phase III ECLIPSE trial evaluating 177Lu-PSMA-I&T met its primary endpoint in patients with mCRPC.

What is Metastatic Prostate Cancer?

Metastatic prostate cancer is an advanced stage of prostate cancer in which cancer cells spread beyond the prostate gland to distant organs and tissues, most commonly the bones, lymph nodes, liver, and lungs. The disease is categorized into metastatic castration-sensitive prostate cancer (mCSPC) and metastatic castration-resistant prostate cancer (mCRPC) based on responsiveness to androgen deprivation therapy. Symptoms may include bone pain, fatigue, urinary complications, spinal cord compression, and reduced quality of life. Advances in hormonal therapy, targeted treatments, radioligand therapy, and precision medicine continue to improve outcomes for patients with metastatic disease.

Metastatic Prostate Cancer Epidemiology Segmentation

The Metastatic Prostate Cancer epidemiology section provides insights into the historical and current patient pool and forecasted trends across the seven major markets. The report offers detailed epidemiological analysis for the study period 2022–2036 segmented into:

• Total Prevalent Cases of Prostate Cancer

• Five-year Prevalent Cases of Prostate Cancer

• Clinical Stage-specific Cases of Prostate Cancer

• Age-specific Cases of Prostate Cancer

• Total Prevalent Cases of Metastatic Prostate Cancer

• mCSPC Cases

• mCRPC Cases

• Country-specific Patient Population

Scope of the Metastatic Prostate Cancer Market Report

• Therapeutic Assessment: Metastatic Prostate Cancer current marketed and emerging therapies

• Metastatic Prostate Cancer Market Dynamics: Key Market Forecast Assumptions of Emerging Drugs and Market Outlook

• Key Companies: Pfizer, Merck, Orion, Curium, Telix Pharmaceuticals, AstraZeneca, Novartis, Exelixis, Ipsen Pharma, Takeda, Merus, Bristol Myers Squibb, Arvinas, and others

• Key Therapies: Opevesostat, Mevrometostat, TLX591, 177Lu-PSMA-I&T, CABOMETYX, PT-112, ARV-766, FPI-2265, TRUQAP, XTANDI, PLUVICTO, LYNPARZA, TALZENNA, AKEEGA, and others

• Competitive Intelligence Analysis: SWOT Analysis and Market Entry Strategies

• Unmet Needs, KOL Views, Analyst Views, Market Access, and Reimbursement Assessment

To know more about Metastatic Prostate Cancer companies working in the treatment market, visit Metastatic Prostate Cancer Clinical Trials and Therapeutic Assessment.

Table of Contents

1. Metastatic Prostate Cancer Market Report Introduction

2. Executive Summary for Metastatic Prostate Cancer

3. SWOT Analysis of Metastatic Prostate Cancer

4. Metastatic Prostate Cancer Patient Share (%) Overview at a Glance

5. Metastatic Prostate Cancer Market Overview at a Glance

6. Metastatic Prostate Cancer Background and Overview

7. Metastatic Prostate Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Metastatic Prostate Cancer

9. Metastatic Prostate Cancer Current Treatment and Medical Practices

10. Metastatic Prostate Cancer Unmet Needs

11. Metastatic Prostate Cancer Emerging Therapies

12. Metastatic Prostate Cancer Market Outlook

13. Country-Wise Metastatic Prostate Cancer Market Analysis (2022–2036)

14. Metastatic Prostate Cancer Market Access and Reimbursement

15. Metastatic Prostate Cancer Market Drivers

16. Metastatic Prostate Cancer Market Barriers

17. Metastatic Prostate Cancer Appendix

18. Metastatic Prostate Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through its subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services